Lilly seeks to block imports of cancer drug copy

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. asked a U.S. trade agency on Thursday to block Hospira Inc. from selling a generic version of the cancer treatment Gemzar, saying the drug violates a patent on the process for making the active ingredient.

Lilly’s complaint to the U.S. International Trade Commission in Washington claims Hospira’s gemcitabine, Gemzar’s active ingredient, infringes a patent expiring in February 2014.

Global sales of Gemzar, used to treat lung, breast, pancreatic and ovarian cancer, fell about 14 percent to $905.8 million in the nine months ended in September, the Indianapolis-based company said Oct. 21.

Hospira began selling gemcitabine in November after Lilly lost an appeals court ruling that said a separate patent expiring in May 2013 was invalid.

The patented method is “the most commercially viable process available for manufacturing gemcitabine” and “involves less steps, higher yields and lower costs,” Lilly said in its complaint. Hospira has refused to provide records on the process it uses to make gemcitabine, according to the complaint.

Lilly is committed to protecting its intellectual property, Mark Taylor, a company spokesman, said in an e-mail Friday. Officials with Lake Forest, Ill.-based Hospira didn’t immediately return a message seeking comment.

The ITC has the power to bar imports of products that infringe U.S. patents and typically completes investigations in about 15 months.

Hospira sued Lilly in October. It’s seeking a court ruling that its process wouldn’t infringe the patent.

Lilly is facing generic competition for its three biggest products in the next two years: schizophrenia drug Zyprexa, antidepressant Cymbalta and the insulin Humalog. The three drugs generated $9.95 billion in 2009 sales, or about 46 percent of the company’s total revenue.


  • idiots
    stop issuing patents for medicine that saves lives. the pharmcos will become extremely competitive, and diseaeses will be cured! this behavior only slows medical research to a crawl. for what? a billionaire's profit?

Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.